Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178895 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL25143 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178890 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL2182769 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL17746959 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178762 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178760 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178759 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178761 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178758 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048157-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4676538-A2 | BI-SPECIFIC ADAPTERS AND THEIR USE WITH UNIVERSAL CAR-T CELLS IN THE TREATMENT OF CAIX-EXPRESSING TUMORS | Purdue Research Foundation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20260009799-A1 | CA-IX TARGETING FLUORESCENT PROBES | BRACCO IMAGING S.P.A. (IT) | 2026-01-08 | — | — | US | disclosed |
| US-12508319-B2 | Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-20250352675-A1 | CA-IX TARGETING FLUORESCENT PROBES | BRACCO IMAGING S.P.A. (IT) | 2025-11-20 | — | — | US | disclosed |
| EP-4619411-A1 | DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2025-09-24 | — | — | EP | disclosed |
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| US-20040115774-A1 | Polymer-modified synthetic proteins | AMYLIN PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| CN-1460023-A | Polymer modified bioactive synthetic chemokines and methods of production and use | GRYPHON TREAT CO (US) | 2003-12-03 | — | — | CN | disclosed |
| EP-1318827-A1 | POLYMER-MODIFIED SYNTHETIC PROTEINS | Gryphon Therapeutics, Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002020033-A1 | POLYMER-MODIFIED SYNTHETIC PROTEINS | GRYPHON THERAPEUTICS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-0352249-B1 | NOVEL PLATELET-AGGREGATION INHIBITORS | Monsanto Company (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0541663-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992002542-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1992-02-20 | — | — | WO | disclosed |
| US-4992463-A | Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation | MONSANTO COMPANY (US) | 1991-02-12 | — | — | US | disclosed |
| EP-0352249-A1 | Novel platelet-aggregation inhibitors | Monsanto Company (US) | 1990-01-24 | — | — | EP | disclosed |
| US-4879313-A | ANTICOAGULANTS | MOSANTO COMPANY (US) | 1989-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260009799-A1 | CA-IX TARGETING FLUORESCENT PROBES | CA9, CA12, CA1 | KMT2A 2160/4885HTT 4701/4885EPHX2 455/4885 |
| US-12508319-B2 | Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof | LHCGR, GNRHR, SSTR1 | KMT2A 2359/4885HTT 2159/4885EPHX2 2635/4885 |
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | KMT2A 3904/4885HTT 3352/4885EPHX2 2470/4885 |
| US-20260048157-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | FAP, FIBP, FGFR1 | KMT2A 3796/4885HTT 3730/4885EPHX2 2002/4885 |
| US-20250352675-A1 | CA-IX TARGETING FLUORESCENT PROBES | CA9, CA4, CA7 | KMT2A 2697/4885HTT 4754/4885EPHX2 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.